Benchtop Kit Advantage The Asteria benchtop kit enables high-throughput single-cell RNA-seq on the lab bench, presenting a compelling entry point for academic and biotech customers seeking rapid, hands-on scRNA-seq capabilities without full core facility dependence.

Hydrogel Technology Scipio’s hydrogel-based single-cell RNA-seq approach differentiates the product by enabling cell-by-cell transcriptomics directly on-site, a selling point for pharma, CROs, and biotech groups aiming for streamlined workflows and tighter data control.

Strategic Partnerships Prior distribution partnerships across Europe and the UK with Ozyme, BioCat, Thistle Scientific, Witec, and others indicate a proven channel model; engaging similar regional distributors or CRO partners could accelerate recovery and revenue re-entry.

Market and Growth Gap With revenue under one million and recent cessation of operations, there is an opportunity to position Scipio’s technology as a niche-enabled alternative to core facilities, targeting small-to-mid biotech firms and academic labs seeking agile scRNA-seq solutions.

International Footprint Existing European footprint and incubator presence at Paris Santé Cochin offer credibility and local access; leveraging this base for targeted outreach to European academic consortia and pharma labs could unlock early-adopter deals and pilot programs.